Zevra Therapeutics Inc [ZVRA] stock is trading at $7.95, up 3.65%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ZVRA shares have gain 9.96% over the last week, with a monthly amount drifted -16.40%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Zevra Therapeutics Inc [NASDAQ: ZVRA] stock has seen the most recent analyst activity on July 02, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $26. On October 07, 2024, Guggenheim initiated with a Buy rating and assigned a price target of $20 on the stock. Maxim Group reiterated its Buy rating and increased its price target to $25 on September 24, 2024. JMP Securities initiated its recommendation with a Mkt Outperform and recommended $17 as its price target on September 24, 2024. Maxim Group reiterated a Buy rating for this stock on April 02, 2024, and upped its price target to $18. In a note dated March 12, 2024, William Blair initiated an Outperform rating.
Zevra Therapeutics Inc [ZVRA] stock has fluctuated between $6.19 and $13.16 over the past year. Currently, Wall Street analysts expect the stock to reach $21.33 within the next 12 months. Zevra Therapeutics Inc [NASDAQ: ZVRA] shares were valued at $7.95 at the most recent close of the market. An investor can expect a potential return of 168.3% based on the average ZVRA price forecast.
Analyzing the ZVRA fundamentals
Zevra Therapeutics Inc [NASDAQ:ZVRA] reported sales of 62.02M for the trailing twelve months, which represents a growth of 481.73%. Gross Profit Margin for this corporation currently stands at 0.72% with Operating Profit Margin at -1.92%, Pretax Profit Margin comes in at 0.34%, and Net Profit Margin reading is 0.04%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.04 and Total Capital is -0.52. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.53.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.63 points at the first support level, and at 7.30 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.16, and for the 2nd resistance point, it is at 8.36.
Ratios To Look Out For
For context, Zevra Therapeutics Inc’s Current Ratio is 7.85. Further, the Quick Ratio stands at 7.81, while the Cash Ratio is 1.65. Considering the valuation of this stock, the price to sales ratio is 7.20, the price to book ratio is 3.74.
Transactions by insiders
Recent insider trading involved FAVORITO TAMARA A, Director, that happened on Sep 12 ’25 when 3175.0 shares were purchased. Director, Shih Alvin completed a deal on Sep 12 ’25 to buy 20000.0 shares. Meanwhile, Director Bode John B bought 5000.0 shares on Aug 19 ’25.
